Attor­ney Gen­er­al Ken Pax­ton Sues Big Phar­ma Drug Man­u­fac­tur­ers and Phar­ma­cy Ben­e­fit Man­agers for Con­spir­a­cy That Increased Insulin Prices by 1,000%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MH

Go back to Attor­ney Gen­er­al Ken Pax­ton Sues Big Phar­ma Drug Man­u­fac­tur­ers and Phar­ma­cy Ben­e­fit Man­agers for Con­spir­a­cy That Increased Insulin Prices by 1,000%

TD Cowen Upgrades CVS Health (CVS) to Buy

October 4, 2024 5:30 AM EDT

TD Cowen analyst Charles Rhyee upgraded CVS Health (NYSE: CVS) from Hold to Buy with a price target of $85.00 (from $59.00).

The analyst comments "We upgrade CVS to Buy from Hold, post release of 2025 MA plan benefits, which show CVS saw meaningful reductions... More